**PHASE II STUDY DESIGN**

**STUDY OBJECTIVES**
- Evaluate the efficacy, safety and tolerability of HF10 at 1x10^7 TCID50/mL in combination with 3mg/kg ipilimumab (ipi) in patients with Stage IIIB, Stage IIIC, or Stage IV unresectable or metastatic malignant melanoma.

**DISCUSSION/CONCLUSIONS**
Treatment with HF10 plus ipilimumab was well-tolerated. Of 46 patients enrolled and treated, 39 patients were assessable/uncertainly history and confirmed diagnosis of metastatic malignant melanoma metastatic (confirmation). The combination HF10 and ipilimumab treatment demonstrated a favorable benefit/risk profile and encouraging antitumor activity in pts with stage IIIB, IIIC, or IV unresectable or metastatic malignant melanoma.

**ACKNOWLEDGEMENTS**
- Patients, their families and caregivers
  - Dr. Atsushi Nishioka – Nagoya University
  - Studies were funded by TaKaRa Bio Inc.